What is King Pharmaceuticals's gross premiums written (note 5)?

King Pharmaceuticals (KG) reported gross premiums written (note 5) of $2.66M in Q1 2026.

What does gross premiums written (note 5) mean?

The total amount of premiums on insurance policies issued by an insurer before deductions for reinsurance cessions. It represents the top-line volume of business underwritten by the company during a specific period. This metric is a primary indicator of market reach and sales activity within the insurance sector.

King Pharmaceuticals KG Gross premiums written (Note 5)

Gross premiums written (Note 5) at other companies

SiriusPointSPNT

——

Segments

By geography

See full

Other (predominantly Europe)$6.29M—

North America-$195K—

By segment

See full

Legacy Reinsurance$2.66M—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PremiumsWrittenGross.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's gross premiums written (note 5).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's gross premiums written (note 5)?: King Pharmaceuticals (KG) reported gross premiums written (note 5) of $2.66M in Q1 2026.
What does gross premiums written (note 5) mean?: The total amount of premiums on insurance policies issued by an insurer before deductions for reinsurance cessions. It represents the top-line volume of business underwritten by the company during a specific period. This metric is a primary indicator of market reach and sales activity within the insurance sector.